New findings about endocrine therapy for breast cancer

Breast

Volumn 12, Issue 6, 2003, Pages 368-372

  Davidson, Nancy E ^a   Visvanathan, Kala ^a   Emens, Leisha ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anastrozole; Ovarian suppression; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; EXEMESTANE; FLUOROURACIL; FULVESTRANT; GOSERELIN; LETROZOLE; METHOTREXATE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR; TAMOXIFEN;

AMENORRHEA; ARTICLE; BLEEDING; BREAST CANCER; CANCER HORMONE THERAPY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FRACTURE; HORMONE RESPONSE; HOT FLUSH; HUMAN; LONG TERM CARE; MENOPAUSAL SYNDROME; MUSCULOSKELETAL DISEASE; PREMENOPAUSE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; VAGINA DISCHARGE; VEIN THROMBOSIS;

EID: 0346888602     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00138-3     Document Type: Article

References (15)

1. NIH Consensus Development Panel. NIH Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1-3, 2000. J Natl Cancer Inst 2001; 93: 979-989.
2. Goldhirsch A, Glick J H, Gelber R D, Coates A S, Senn H J. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol 2001; 19: 3817-3827.
3. Emens L A, Davidson N E. Adjuvant hormonal therapy for premenopausal women with breast cancer. Clin Cancer Res 2003: 9: 486s-494s.
4. Visvanathan K, Davidson N E. Aromatase inhibitors as adjuvant therapy in breast cancer. Oncology 2003; 17: 335-342.
5. Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. J Clin Oncol 2002; 20: 4628-4635.
6. Castiglione-Gertsch M, O'Neill A, Gelber R D et al. Is the addition of adjuvant chemotherapy always necessary in node-negative (N-) pre/perimenopausal breast cancer patients who receive goserelin? Proc Am Soc Clin Oncol 2002; 21: 38a.
7. Jakesz R, Hausmaninger H, Kubista E et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group trial 5. J Clin Oncol 2002; 20: 4621-4627.
8. Love R R, Duc N B, Allred D C et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol 2002; 20:2559-2566.
9. Love R R, Duc N B, Havighurst T C et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol 2003; 21: 453-457.
10. Ellis M J, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3608-3616.
11. The ATAC (Arimidex,Tamoxifen Alone or in Combination) Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet 2002; 359: 2131-2139.
12. Winer E P, Hudis C, Burstein H J et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002; 20: 3317-3327.
13. Osborne C K, Pippen J, Jones S E et al. Double-blind randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
14. Howell A, Robertson J F, Quaresma Albano J et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
15. Robertson J F R, Howell A, Abram P, Lichinitser M R, Elledge R. Fulvestrant versus tamoxifen for the first-line treatment of advanced breast cancer (ABC) in postmenopausal women. Ann Oncol 2002; 13 (Suppl 5): 46.